PCSK9 Inhibition in Patients After Heart Transplantation: a Retrospective Review and Literature Analysis.

IF 3.8 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Heart Failure Reports Pub Date : 2023-06-01 Epub Date: 2023-05-08 DOI:10.1007/s11897-023-00604-2

Jeffrey J Chapa, Jonathan C McCollum, Janina Quintero Bisono, Rishika S Prakash, Maya E Guglin, Roopa A Rao

{"title":"PCSK9 Inhibition in Patients After Heart Transplantation: a Retrospective Review and Literature Analysis.","authors":"Jeffrey J Chapa, Jonathan C McCollum, Janina Quintero Bisono, Rishika S Prakash, Maya E Guglin, Roopa A Rao","doi":"10.1007/s11897-023-00604-2","DOIUrl":null,"url":null,"abstract":"Purpose of review: Following cardiac transplantation, patients have an increased risk of developing cardiac allograft vasculopathy and atherosclerotic cardiovascular disease. Therefore, aggressive lipid management is indicated. Some patients do not achieve optimal lipid profiles with statin monotherapy, however, or discontinue statins due to intolerance. In this review, we investigated the use of PCSK9 inhibitors as an alternative treatment for hyperlipidemia following cardiac transplantation.Recent findings: Nine published articles were identified that included 110 patients treated with alirocumab or evolocumab after cardiac transplantation. PCSK9 inhibitors were tolerated by all patients, and each study demonstrated an effective reduction of low-density lipoprotein ranging from 40 to 87% decrease from baseline. In our study, the 110 patients from literature review were added to a cohort of 7 similar patients from our institution for combined analysis. This report supports that PCSK9 inhibitors should be considered following cardiac transplantation when conventional medial therapy is not tolerated or ineffective.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"20 3","pages":"168-178"},"PeriodicalIF":3.8000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Heart Failure Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11897-023-00604-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Following cardiac transplantation, patients have an increased risk of developing cardiac allograft vasculopathy and atherosclerotic cardiovascular disease. Therefore, aggressive lipid management is indicated. Some patients do not achieve optimal lipid profiles with statin monotherapy, however, or discontinue statins due to intolerance. In this review, we investigated the use of PCSK9 inhibitors as an alternative treatment for hyperlipidemia following cardiac transplantation.

Recent findings: Nine published articles were identified that included 110 patients treated with alirocumab or evolocumab after cardiac transplantation. PCSK9 inhibitors were tolerated by all patients, and each study demonstrated an effective reduction of low-density lipoprotein ranging from 40 to 87% decrease from baseline. In our study, the 110 patients from literature review were added to a cohort of 7 similar patients from our institution for combined analysis. This report supports that PCSK9 inhibitors should be considered following cardiac transplantation when conventional medial therapy is not tolerated or ineffective.

查看原文本刊更多论文

心脏移植术后患者的 PCSK9 抑制：回顾性综述和文献分析。

审查目的：心脏移植后，患者发生心脏异体移植血管病变和动脉粥样硬化性心血管疾病的风险增加。因此，应积极进行血脂管理。然而，有些患者在使用他汀类药物单药治疗后血脂状况并不理想，或因不耐受而停用他汀类药物。在这篇综述中，我们研究了使用 PCSK9 抑制剂作为心脏移植后高脂血症的替代治疗方法：我们发现了九篇已发表的文章，共纳入了 110 名接受心脏移植手术后使用阿利珠单抗或依维莫司单抗治疗的患者。所有患者都能耐受 PCSK9 抑制剂，而且每项研究都显示低密度脂蛋白从基线下降了 40% 到 87% 不等。在我们的研究中，我们将文献综述中的 110 例患者与本机构的 7 例类似患者进行了合并分析。本报告支持在心脏移植术后，当常规药物治疗不能耐受或无效时，应考虑使用 PCSK9 抑制剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Heart Failure Reports Medicine-Emergency Medicine

CiteScore

5.30

自引率

0.00%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of heart failure. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as investigative, pharmacologic, and nonpharmacologic therapies, pathophysiology, and prevention. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.